Slow Capital Inc. Takes Position in Danaher Co. (NYSE:DHR)

Slow Capital Inc. purchased a new stake in Danaher Co. (NYSE:DHR) in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 14,551 shares of the conglomerate’s stock, valued at approximately $4,048,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Tsfg LLC boosted its holdings in shares of Danaher by 733.3% in the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after buying an additional 88 shares during the period. nVerses Capital LLC acquired a new position in shares of Danaher in the second quarter valued at approximately $25,000. CarsonAllaria Wealth Management Ltd. acquired a new position in shares of Danaher in the second quarter valued at approximately $25,000. Redmont Wealth Advisors LLC acquired a new position in shares of Danaher in the first quarter valued at approximately $30,000. Finally, MFA Wealth Advisors LLC acquired a new position in shares of Danaher in the second quarter valued at approximately $51,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Price Performance

Shares of DHR opened at $274.38 on Friday. The firm has a market capitalization of $203.23 billion, a PE ratio of 46.50, a PEG ratio of 4.49 and a beta of 0.83. The company’s 50-day moving average is $270.72 and its 200-day moving average is $259.92. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $281.70. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.15. The company had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The company’s revenue was down 2.9% on a year-over-year basis. During the same period in the prior year, the firm earned $2.05 earnings per share. Equities analysts forecast that Danaher Co. will post 7.59 EPS for the current year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be given a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.39%. The ex-dividend date of this dividend is Friday, September 27th. Danaher’s dividend payout ratio is 18.31%.

Insider Buying and Selling

In related news, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the transaction, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Rainer Blair sold 9,007 shares of the firm’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the sale, the chief executive officer now directly owns 97,983 shares in the company, valued at approximately $27,435,240. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares in the company, valued at approximately $1,130,374.44. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 39,659 shares of company stock valued at $11,042,433. 11.10% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on DHR. TD Cowen increased their target price on shares of Danaher from $290.00 to $310.00 and gave the stock a “buy” rating in a report on Wednesday, July 24th. Wells Fargo & Company began coverage on shares of Danaher in a report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 target price for the company. Stephens began coverage on shares of Danaher in a report on Tuesday, October 1st. They set an “overweight” rating and a $315.00 target price for the company. Stifel Nicolaus increased their target price on shares of Danaher from $235.00 to $250.00 and gave the stock a “hold” rating in a report on Wednesday, July 24th. Finally, Robert W. Baird increased their target price on shares of Danaher from $271.00 to $278.00 and gave the stock an “outperform” rating in a report on Wednesday, July 24th. Seven investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $282.12.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.